Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-12-30

Clinical Trial Update: IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy [Phase 3]

View source ↗

Summary

Phase 3 trial of intravenous immunoglobulin (IVIG) in VGKC-complex antibody-associated autoimmune epilepsy was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Intravenous Immunoglobulin (IVIG)

Snippet

Sponsor: Mayo Clinic | Conditions: Autoimmune Epilepsy | Phase 3 | Status: TERMINATED | Results posted: 2019-12-30